Parenteral Drugs rallies on sale of unit by subsidiary company
Goa Formulations Limited, a subsidiary company has sold its pharmaceutical manufacturing unit at Goa to Fresenius Kabi India Private Limited for a total consideration of Rs 200 crore.
Parenteral Drugs (India) has rallied over 8% to Rs 129 after the company said Goa Formulations Limited, a subsidiary company has sold its pharmaceutical manufacturing unit at Goa to Fresenius Kabi India Private Limited for a total consideration of Rs 200 crore.
“The subsidiaries of the company M/s. Goa Formulations Limited has executed an agreement with M/s. Fresenius Kabi India Private Limited to sell its only pharmaceutical manufacturing unit at Goa at a consideration of Rs 200 crore,” Parenteral Drugs India said in a regulatory filing.
Parenteral Drugs (India) Ltd is the holding company of Goa Formulations Limited.
The stock opened at Rs 129 and hit a 52-week high of Rs 131 on BSE. Around 32,400 shares have changed hands on both the counters on BSE and NSE
“The subsidiaries of the company M/s. Goa Formulations Limited has executed an agreement with M/s. Fresenius Kabi India Private Limited to sell its only pharmaceutical manufacturing unit at Goa at a consideration of Rs 200 crore,” Parenteral Drugs India said in a regulatory filing.
Parenteral Drugs (India) Ltd is the holding company of Goa Formulations Limited.
The stock opened at Rs 129 and hit a 52-week high of Rs 131 on BSE. Around 32,400 shares have changed hands on both the counters on BSE and NSE